Last updated on February 2020

A Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With HIV-1


Brief description of study

This study will be conducted in two stages and will test the safety/tolerability, pharmacokinetics (how the body handles study drug) and pharmacodynamics (effects on the immune system and the virus) of the study drug ABBV-181 in HIV-1 infected participants undergoing ART interruption.

Clinical Study Identifier: NCT04223804

Find a site near you

Start Over